par de Borchgrave d'Alténa, Valérie;Delvaux, V;De Tourtchaninoff, Marianne;Dubru, J M;Ghariani, S;Grisar, T;Legros, Benjamin 
;Ossemann, M;Sadzot, B.;Tugendhaft, P;Van Bogaert, Patrick ;van Rijckevorsel, Kenou;Groupe de travail des centres francophones de référence de l'epilepsie réfractaire,
Référence Acta neurologica belgica, 102, 1, page (6-10)
Publication Publié, 2002-03
;Ossemann, M;Sadzot, B.;Tugendhaft, P;Van Bogaert, Patrick ;van Rijckevorsel, Kenou;Groupe de travail des centres francophones de référence de l'epilepsie réfractaire, Référence Acta neurologica belgica, 102, 1, page (6-10)
Publication Publié, 2002-03
Article révisé par les pairs
| Résumé : | The choice of treatment of newly diagnosed epilepsy involves many factors such as age, sex, life style, general health and concomitant medication. The seizure type, syndrome, and the pharmacology, efficacy and safety of the antiepileptic drugs (AEDs) should also be considered. Some of the new AEDs appear to provide at least equivalent efficacy with better tolerability. Some of these drugs have the potential to become drugs of first choice in newly diagnosed epilepsy. At the present time, we also must consider the criteria of reimbursement of these drugs. In this paper, we try to describe common and practical strategies to start a treatment of newly diagnosed epilepsy. |
